Articles with the keyword: 


A lean and mean VEGF for cancer cells
sumsung submitted, created time 1 year 1 week (www.jcb.org)
Cells that suffer DNA damage start pumping out a previously undiscovered version of the angiogenesis promoter VEGF, as Mineur et al. report. The variant, which is tough and mobile, might help cancer cells tap new sources of blood. 


Quantitative PET imaging finds early determination of effectiveness of cancer treatment
richard submitted, created time 1 year 2 months (interactive.snm.org)
With positron emission tomography imaging, seeing is believing: evaluating a patient's response to chemotherapy for non-Hodgkin lymphoma typically involves visual interpretation of scans of cancer tumors. Researchers have found that measuring a quantitative index -- one that reflects the reduction of metabolic activity after chemotherapy first begins -- adds accurate information about patients' responses to first-line chemotherapy, according to a study in the October issue of the Journal of Nuclear Medicine. 


Analysis of breast and colon cancer genes finds many areas of differences between tumors
kitty submitted, created time 1 year 2 months (www.eurekalert.org)
Researchers from University Hospitals Ireland Cancer Center and Case Western Reserve University School of Medicine are part of a new national study that has analyzed more than 18,000 genes, including 5,000 previously unmapped genes, from breast and colorectal tumors. The study shows a great number of genetic differences between breast and colon cancer tumors, leading the researchers to conclude that new drugs must be developed that can hit these newly identified genetic targets in a manner specific to each different individual's tumor. 


sumsung submitted, created time 1 year 3 months (www.pnas.org)
Cancer is a disease of aging. The accumulation of mutations in individual cells over a lifetime is thought to be the reason. In this work, we explored an additional hypothesis: could p53 function decline with age, which would contribute to an enhanced mutation frequency and tumorigenesis in the aging process. 


Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth
sumsung submitted, created time 1 year 5 months (www.pnas.org)
Intravenously administered bacteria reportedly accumulate in tumors. Furthermore, systemic administration of attenuated Salmonella typhimurium has little or no significant side-effects in humans. 


sumsung submitted, created time 1 year 5 months (www.pnas.org)
As its name suggests, tumor necrosis factor (TNF) is known to induce cytotoxicity in a wide variety of tumor cells and cell lines. 


In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
bianjie submitted, created time 1 year 5 months (www.pnas.org)
Adoptive transfer therapy of in vitro-expanded tumor-specific cytolytic T lymphocytes (CTLs) can mediate objective cancer regression in patients. Yet, technical limitations hamper precise monitoring of posttherapy T cell responses. 


Decoding Gene Expression In Cancer Tumors Using Noninvasive Imaging
addict submitted, created time 1 year 7 months (www.medicalnewstoday.com)
By correlating images of cancerous liver tissue with gene expression patterns, a research team led by a radiologist at the University of California, San Diego (UCSD) School of Medicine has developed tools that may some day allow physicians to view a CT image of a cancer tumor and discern its genetic activity. The study, designed to help doctors obtain the molecular details of a specific tumor or disease without having to do an invasive biopsy procedure, are published online in Nature Biotechnology. 


athena submitted, created time 1 year 7 months (www.jci.org)
"Protein geranylgeranyltransferase type I (GGTase-I) is responsible for the posttranslational lipidation of CAAX proteins such as RHOA, RAC1, and cell division cycle 42 (CDC42). Inhibition of GGTase-I has been suggested as a strategy to treat cancer and a host of other diseases. Although several GGTase-I inhibitors (GGTIs) have been synthesized, they have very different properties, and the effects of GGTIs and GGTase-I deficiency are unclear. One concern is that inhibiting GGTase-I might lead to severe toxicity 


Imaging finding goes boldly into genetic frontiers
julie submitted, created time 1 year 7 months (www.reuters.com)
"Researchers have figured out how to spot genetic changes in the body that may help determine whether a tumor is shrinking or a drug is working, using standard imaging techniques.
" 


Finding goes boldly into genetic frontiers
julie submitted, created time 1 year 7 months (feeds.feedburner.com)
"Researchers have figured out how to spot genetic changes in the body that may help determine whether a tumor is shrinking or a drug is working, using standard imaging techniques." 


Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
amanda submitted, created time 1 year 7 months (www.biologynews.net)
"The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies. One of the primary challenges associated with this type of therapy is delivering the therapeutic agent into the body and then to the tumor in a safe and effective manner 


badboy submitted, created time 1 year 7 months (jama.ama-assn.org)
"Hepatitis C virus infection confers a 20% to 30% increased risk of non-Hodgkin lymphoma overall, and a 3-fold higher risk of Waldenström macroglobulinemia, a low-grade lymphoma. Risks were also increased for cryoglobulinemia. These results support an etiological role for HCV in causing lymphoproliferation and causing non-Hodgkin lymphoma. " 


MicroRNAs can be tumor suppressors
fiona submitted, created time 1 year 8 months (www.biologynews.net)
"University of Virginia researchers have discovered that microRNAs, a form of genetic material, can function as tumor suppressors in laboratory studies. " 


Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
julie submitted, created time 1 year 8 months (www.biologynews.net)
"A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center. The gene, FUS1, also was found to be active in the metastatic non-small cell lung cancer tumors." 